Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
Tuesday, April 07, 2020 11:26:06 PM
Professor Émile Ferrari, the head of the cardiology department at Nice University Hospital in Nice, France, told a local news outlet he has had to stop treating patients with hydroxychloroquine combined with azithromycin because of adverse cardiac effects.
Nice University Hospital was selected as part of a trial to test some coronavirus treatments, including hydroxychloroquine. Ferrari told Nice-Matin newspaper that one patient experienced a serious complication and that the treatment was stopped immediately.
The cardiologist reiterated what health experts have warned about the drug combination: that the drugs can trigger arrhythmia, which can lead to a fatal heart attack in some patients, especially those who have heart conditions or are on certain medications.
In the United States, doctors have recommended screening patients with an electrocardiogram to prevent the drugs from being given to the 1 percent of patients at greatest risk of a cardiac event, The Washington Post has reported. The drugs also can cause vision loss called retinopathy with long-term use, and chloroquine has been associated with psychosis.
So far, there is no clear evidence that the drugs work to treat the coronavirus, though their antiviral properties have been tested in labs. Rigorous clinical trials that test the drugs in humans against placebos have not been completed.
Ferrari told Nice-Martin that although covid-19 can kill, the treatment should not be more harmful than the disease.
https://www.washingtonpost.com/world/2020/04/07/coronavirus-latest-news/#link-K4DJOFMFVVBEPGPHM2NFG3A4BI
* Never borrow to invest.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM